Log in | Register

Understanding therapeutic targets in thrombotic thrombocytopenic purpura

Bérangère S. Joly| Karen Vanhoorelbeke| Agnès Veyradier
Understanding the Disease
Volume 43, Issue 9 / September , 2017

Pages 1398 - 1400

No abstract available.

References

  1. Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584
    • View reference on publisher's website
    • View reference on PubMed
  2. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594
    • View reference on publisher's website
    • View reference on PubMed
  3. Zheng XL (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211–225
    • View reference on publisher's website
    • View reference on PubMed
  4. Pillai VF, Bao J, Zander CB et al (2016) Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP. Blood 128:110–119
    • View reference on publisher's website
    • View reference on PubMed
  5. Sadler JE (2015) What’s new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Am Soc Hematol Educ Progr 2015:631–636
  6. Mannucci PM (2015) Understanding organ dysfunction in thrombotic thrombocytopenic purpura. Intensive Care Med 41:715–718
  7. Mariotte E, Azoulay E, Galicier L et al (2016) Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e237–e245
    • View reference on publisher's website
    • View reference on PubMed
  8. Joly BS, Stepanian A, Leblanc T et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol. doi:10.1016/S2352-3026(16)30125-9
    • View reference on PubMed
  9. Rock GA, Shumak KH, Buskard NA et al (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med 325:393–397
    • View reference on publisher's website
    • View reference on PubMed
  10. Plaimauer B, Kremer Hovinga JA, Juno C et al (2011) Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies. J Thromb Haemost 9:936–944
    • View reference on publisher's website
    • View reference on PubMed
  11. Vanhoorelbeke K, De Meyer SF (2013) Animal models for thrombotic thrombocytopenic purpura. J Thromb Haemost 11:2–10
    • View reference on publisher's website
    • View reference on PubMed
  12. Cai P, Luo H, Xu H et al (2015) Recombinant ADAMTS13 attenuates brain injury after intracerebral hemorrhage. Stroke 46:2647–2653
    • View reference on publisher's website
    • View reference on PubMed
  13. Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125:3860–3867
    • View reference on publisher's website
    • View reference on PubMed
  14. Scully M, Knoebl P, Kentouche K et al (2016) Pharmacodynamic profile of a recombinant ADAMTS13 (BAX930) in hereditary thrombotic thrombocytopenic purpura [Upshaw-Schulman syndrome (USS)]. Blood 128:135
  15. George JN (2012) Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 87(Suppl. 1):S88–S91
    • View reference on publisher's website
    • View reference on PubMed
  16. Jilma-Stohlawetz P, Gorczyca ME, Jilma B et al (2011) Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 105:545–552
    • View reference on publisher's website
    • View reference on PubMed
  17. Peyvandi F, Scully M, Kremer Hovinga JA et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522
    • View reference on publisher's website
    • View reference on PubMed
  18. Chen J, Reheman A, Gushiken FC et al (2011) N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice. J Clin Investig 12:593–603
    • View reference on publisher's website
  19. Jian C, Xiao J, Gong L et al (2012) Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 119:3836–3843
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement